logo
  

Vanda Settles HETLIOZ Patent Litigation With MSN

Vanda Pharmaceuticals Inc. (VNDA) said that it has reached a License Agreement with MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and Impax Laboratories to settle Vanda's patent litigation against MSN regarding MSN's Abbreviated New Drug Application seeking approval of its generic version of Vanda's HETLIOZ or tasimelteon.

As per the license deal, Vanda granted MSN and Impax a non-exclusive license to manufacture and commercialize MSN's version of HETLIOZ in the U.S. effective March 13, 2035, unless prior to that date Vanda obtains pediatric exclusivity for HETLIOZ, in which case, the license will be effective July 27, 2035. MSN and Impax may enter the market earlier under certain limited circumstances.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cargill, Inc., a privately held food company, is recalling certain chocolate products containing recalled Jif peanut butter due to the potential for salmonella contamination, the U.S. Food and Drug Administration said. The recall involves 795, 8-ounce boxes of Wilbur brand products, such as Milk and Dark Chocolate Covered Peanut Butter Ritz Crackers, Peanut Butter Meltaways... The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals, Inc.'s Dupixent (dupilumab) to treat eosinophilic esophagitis or EoE, a chronic immune disorder. It is the first FDA approval to treat EoE in adults and pediatric patients 12 years and older weighing at least 40 kilograms. Food products maker J. M. Smucker Co. has recalled select Jif peanut butter products sold in the United States due to potential Salmonella contamination, the U.S. Food and Drug Administration said. The recall involves various creamy, crunchy, natural, no added sugar, and reduced fat peanut butter, among others with lot codes 1274425 - 2140425.
Follow RTT